UvA-DARE (Digital Academic Repository)
Clinical pharmacology in leishmaniasis: treatment optimization of a neglected disease
Dorlo, T.P.C.
Publication date 2013
Link to publication
Citation for published version (APA): Dorlo, T. P. C. (2013). Clinical pharmacology in leishmaniasis: treatment optimization of a neglected disease.
General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
Download date:03 Oct 2021 List of Publications
Dorlo TPC, Boelaert M, Beijnen JH, Ravinetto R. Universal access to quality medicines: prioritisation of a-priori solutions. The Lancet Infectious Diseases 2012; 12:829-30.
Dorlo TPC, Ravinetto R, Beijnen JH, Boelaert M. Substandard medicines are the priority for neglected tropical diseases. British Medical Journal 2012; 345:e7518.
Renckens CNM & Dorlo TPC. Please, let not Western quackery replace traditional medicine in Africa. Tropical Medicine & International Health 2012; in press.
Visvesvara GS, Atkins J, Sriram R, Dorlo TPC, Guglielmo J, Qvarnstrom Y, Kucerova Z, Hayes T, Roy SL. Multidisciplinary investigations of Balamuthia mandrillaris infection in a pediatric patient treated with miltefosine. Submitted.
Ravinetto RM, Caudron JM, Dorlo TPC, Prashanth NS. The global impact of Indian generics: public health should prevail over commercial interests and regulatory inadequacy. Submitted.
Dorlo TPC, Balasegaram M, Beijnen JH, de Vries PJ. Biomarkers to monitor the treatment response in leishmaniasis. Submitted.
Dorlo TPC, Rijal S, Ostyn B, de Vries PJ, Singh R, Bhattarai N, Uranw S, Dujardin JC, Boelaert M, Beijnen JH, Huitema ADR. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. Submitted.
Dorlo TPC, Jager NGL, Beijnen JH, Schellens JHM. [Proton-pump inhibitors with systemic corticosteroids: evidence-based medicine?]. Submitted. [In Dutch]
Khalil EA, Weldegebreal T, Younis B, Hurissa Z, Hailu W, Abuzaid AA, Yifru S, Haleke W, El-Hassan AM, Edwards T, Smith p, Omollo R, Dorlo TPC, Schoone GJ, Wasunna M, Kimutai R, Ellis S, Balasegaram M, Musa AM, Hailu A. Ambisome® for the treatment of visceral leishmaniasis in East Africa: a multi-centre randomized trial. Submitted.
Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TPC, Beijnen JH, Vanaerschot M, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, re-infection or non-compliance. Submitted.
300 Uranw S, Ostyn B, Dorlo TPC, Hasker E, Dujardin B, Dujardin JC, Rijal S, Boelaert M. Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal. Tropical Medicine & International Health 2012; in press.
Dorlo TPC, de Vries PJ, Beijnen JH. Miltefosine – a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. Journal of Antimicrobial Chemotherapy 2012; 67:2576-97.
Dorlo TPC, Balasegaram M, Lima MA, de Vries PJ, Beijnen JH, Huitema ADR. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. Journal of Antimicrobial Chemotherapy 2012; 67:1996-2004.
Dorlo TPC, Huitema ADR, Beijnen JH, de Vries PJ. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrobial Agents & Chemotherapy 2012; 56:3864-72.
Dorlo TPC, Eggelte TA, Schoone GJ, de Vries PJ, Beijnen JH. A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal. PLoS Neglected Tropical Diseases 2012; 6:e1544.
Dorlo TPC, Eggelte TA, de Vries PJ, Beijnen JH. Characterization and identification of suspected counterfeit miltefosine capsules. Analyst 2012; 137:1265-74.
Byakika-Kibwika P, Lamorde M, Okaba-Kayom V, Mayanja-Kizza H, Hanpithakpong W, Pakker N, Dorlo TPC, Tarning J, Lindegardh N, de Vries PJ, Back D, Khoo S, Merry C. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether-lumefantrine in HIV-infected Uganda adults. Journal of Antimicrobial Chemotherapy 2012; 67:1217-1223.
Dorlo TPC [Faith in Mother Nature? – Judging the orthodoxy of therapies is the pharmacists duty]. Pharmaceutisch Weekblad 2011; 49. [In Dutch]
Dorlo TPC, van Thiel PPAM, Schoone GJ, Stienstra Y, van Vugt M, Beijnen JH, de Vries PJ. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoS Neglected Tropical Diseases 2011; 5:e1436.
Omollo R, Alexander N, Edwards T, Khalil EA, Younis BM, Abuzaid AA, Wasunna M, Njoroge N, Kinoti D, Kirigi G, Dorlo TPC, Ellis S, Balasegaram M, Musa AM. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials 2011; 12:166.
List of Publications 301 Dorlo TPC, Brandsma D, Boogerd W, Haanen JH, Beijnen JH. [Dichloroacetate: a toxic ‘miracle drug’]. Pharmaceutisch Weekblad – Wetenschappelijk Platform 2011; 5:a1137. [In Dutch]
Brandsma D, Dorlo TPC , Haanen JH, Beijnen JH, Boogerd W. Severe encephalopathy and polyneuropathy induced by dichloroacetate. Journal of Neurology 2010; 257:2099- 100.
Dorlo TPC & Kager PA. Comment on: Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2010; 104:84–5.
Dorlo TPC & Timmerman H. [China prospers from herbal export]. Medisch Contact 2009; 46:1900-3. [In Dutch]
Dorlo TPC & Kager PA. Pentamidine: a base/salt confusion. PLoS Neglected Tropical Diseases 2008; 2:e225.
Dorlo TPC, van Thiel PPAM, Huitema ADR, Beijnen JH, de Vries PJ. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrobial Agents & Chemotherapy 2008; 52:2855-60
Dorlo TPC, Hillebrand MJX, Rosing H, Eggelte TA, de Vries PJ, Beijnen JH. Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 2008; 865:55-62
Dorlo TPC, Eggelte TA, Beijnen JH, de Vries PJ. [Miltefosine: a new remedy for leishmaniasis]. Nederlands Tijdschrift voor Geneeskunde 2006; 150:2697-2701. [In Dutch]
302